Drug watch: tracking a rare disease treatment in real patients

This study observed 11 adult patients in Korea who were already taking or starting Soliris for a rare autoimmune disorder called Neuromyelitis Optica Spectrum Disorder (NMOSD). Its main purpose was to collect real-world information on the drug's safety and how well it prevents disease relapses in normal clinical practice, as required by Korean health authorities after the drug's approval. The study did not test a new treatment but monitored patients who were already receiving the standard, approved therapy.